Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis

Clinical Nephrology

Volumn 68, Issue 5, 2007, Pages 287-294

  Abe, M ^a   Kikuchi, F ^b   Kaizu, K ^c   Matsumoto, K ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Yamato Hospital   (Japan)

^c Social Insurance Yokohama Central Hospital   (Japan)

Author keywords

Hemodialysis; Insulin resistance; Pioglitazone; Type 2 diabetes; Voglibose; glucoside inhibitors

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; PIOGLITAZONE; TRIACYLGLYCEROL; VOGLIBOSE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERANCE; EDEMA; FEMALE; FLUID RETENTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; JAPANESE; LIVER DYSFUNCTION; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHABDOMYOLYSIS; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 35748959376     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp68287     Document Type: Article

References (17)

1. Agrawal A, Sautter MC, Jones NP. Effects of rosiglitazone maleate when added to a sulfonylurea regimen in Type 2 diabetics mellitus and mild to moderate renal impairment: a post hoc analysis. Clin Ther. 2003; 25: 2754-2764.
2. Cranberry MC, Schneider EF, Fonseca VA. The role of troglitazone in treating the insulin resistance syndrome. Pharmacotherapy. 1998; 18: 973-987.
3. Defronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991; 14: 173-194.
4. Gisberg H, Plutzky J, Sobel BE. A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering. J Cardiovasc Risk. 1999; 6: 337-346.
5. Goldstein BJ. Rosiglitazone. Int J Clin Pract. 2000; 54: 333-337.
6. Lin SH, Lin YF, Kuo SW, Hsu YJ, Hung YJ. Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD. Am J Kidney Dis. 2003; 42: 774-780.
7. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA. Metabolic effects of troglitazone monotherapy in Type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998; 128: 176-185.
8. Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ. Metabolic and additional vascular effects of thiazolidinediones. Drugs. 2002; 62: 1463-1480.
9. Nesto RW, Bell D, Bonow RQ, Fonseca V, Grandy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione use, fluid retention and congestive heart failure. A consensus statement from the AHA and ADA. Circulation. 2003; 108: 2941-2948.
10. Pedro I, Juan JD. Peroxisome proliferator-activated receptor-γ agonists in renal disease. Eur J Endocrinol. 2006; 154: 613-621.
11. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care. 2003; 26: 172-178.
12. Schwartz S, Raskin P, Fonseca V, Graveline JF. Effect of troglitazone in insulin treated-patients with Type 2 diabetes mellitus. Troglitazone and Exogeneous Insulin Study Group. N Engl J Med. 1998; 338: 861-866.
13. Sone H, Ito H, Ohashi Y. Japan Diabetes Complication Study (JDCS) Group: Obesity and Type 2 diabetes in Japanese patients. Lancet. 2003; 361: 85.
14. Spiegelman BM. PPAR: adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998; 47: 507-514.
15. Staels B, Fruchart J. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes. 2005; 54: 2460-2470.
16. Thompson-Culkin K, Zussman B, Miller AK, Freed MI. Pharmacokinetics of rosiglitazone in patients with end stage renal disease. J Int Med Res. 2002; 30: 391-399.
17. Wong TY, Szeto CC, Chow KM, Leung CB, Lam CWK, Li PKT. Rosiglitazone reduces insulin requirement and C-reactive protein levels in Type 2-diabetic patients receiving peritoneal dialysis. Am J Kidney Dis. 2005; 46: 713-719.